Comprehensive Insights into the Economic Burden of Rheumatoid Arthritis in Latin America: A Systematic Literature Review of Regional Perspectives

被引:0
作者
Maldonado-Restrepo, Angela Isabel [1 ]
Acelas-Gonzalez, Gabriel E. [2 ]
Rodriguez-Vargas, Gabriel-Santiago [3 ,4 ]
Rodriguez-Linares, Pedro [3 ]
Gonzalez-Rodriguez, Javier-Leonardo [1 ]
Rojas-Villarraga, Adriana [5 ]
Santos-Moreno, Pedro [6 ]
机构
[1] Univ Rosario, Sch Management & Business, Res Grp Management & Business, Bogota, Colombia
[2] Fdn Univ Ciencias Salud FUCS, Res Vicerectory, Bogota, Colombia
[3] Biomab Ctr Rheumatoid Arthrit, Res Dept, Bogota, Colombia
[4] Univ El Bosque, Dept Internal Med, Bogota, Colombia
[5] Fdn Univ Ciencias Salud FUCS, Res Inst, Bogota, Colombia
[6] Biomab Ctr Rheumatoid Arthrit, Sci Direct, Bogota, Colombia
关键词
economic burden; Latin America; rheumatoid arthritis; COST-EFFECTIVENESS ANALYSIS; 2ND LINE TREATMENT; HEALTH-CARE; BIOLOGICAL THERAPY; SPECIALIZED CENTER; ANTI-TNF; ETANERCEPT; IMPACT; BIOSIMILARS; TOCILIZUMAB;
D O I
10.2147/CEOR.S498994
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose: Rheumatoid arthritis (RA) affects approximately 0.3 to 1.2% of the world's population. The objective of this study was to identify the existing literature on economic evaluations of RA in Latin America. Patients and Methods: Studies of economic evaluations of patients with RA from 2000 to 2023 were analyzed using the databases PubMed, Scopus, Web of Science, Embase, Cochrane, and the Virtual Health Library following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Study quality was assessed using the Joanna Briggs Institute (JBI) tool, and qualitative analysis was done (following SwiM guidelines). Results: A total of 851 articles were identified. Following the application of inclusion criteria to titles and abstracts, 117 articles were initially considered eligible. Of these, 42 were excluded due to population or outcome-based errors, leaving 27 articles and 48 abstracts for analysis. Duplicates were removed prior to this process. The included studies involved various designs: cross-sectional, longitudinal, prospective, and retrospective. Brazil accounted for the highest proportion of publications (33.3%), followed by Colombia and Mexico, each contributing 26%. Most economic studies focused on cost analysis (86%), while cost-effectiveness studies and costutility studies represented 7.4% and 3.3%, respectively. Predominant perspectives included third-party payer 26%, insurers 14.8%, social providers 7.4%, and mixed providers 3.7%. In terms of publications of abstracts, Colombia leaded at 35.4%. The predominant perspective was that of the provider 66.6%, including the general perspective (37.5%), private (34.3%), public (22%), and mixed (6.2%) and the perspective of third-party payers (33.3%). Conclusion: Economic evaluations of rheumatoid arthritis in Latin America remain limited, with most studies focusing on cost analysis. Brazil, Colombia, and Mexico lead in publications, primarily from a provider perspective. Greater emphasis on costeffectiveness and broader economic evaluations is needed to guide health policy in the region.
引用
收藏
页码:349 / 373
页数:25
相关论文
共 108 条
[1]  
Aguirre A, 2009, VALUE HEALTH, V12, pA522
[2]   Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK [J].
Aladul, Mohammed I. ;
Fitzpatrick, Raymond W. ;
Chapman, Stephen R. .
BIODRUGS, 2017, 31 (06) :533-544
[3]   COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN INSTITUTIONAL MARKET IN ECUADOR [J].
Albuja, M. F. ;
Torres, F. G. ;
Mould, J. ;
Estevez, C. .
VALUE IN HEALTH, 2013, 16 (07) :A717-A717
[4]   WHAT IS THE VALUE OF THE NEW KID ON THE BLOCK?: TOCILIZUMAB VERSUS ABATACEPT FOR RHEUMATOID ARTHRITIS IN COLOMBIA [J].
Alfonso-Cristancho, R. ;
Aiello, E. C. ;
Roa, C. N. ;
Valencia, J. E. .
VALUE IN HEALTH, 2011, 14 (07) :A563-A563
[5]   COST-EFFECTIVENESS OF ABATACEPT OR INFLIXIMAB IN RHEUMATOID ARTHRITIS IN COLOMBIA [J].
Alfonso-Cristancho, R. ;
Aiello, E. C. ;
Roa, C. N. .
VALUE IN HEALTH, 2011, 14 (03) :A127-A127
[6]   COST-EFFECTIVENESS OF BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS IN A LARGE PUBLIC HOSPITAL IN ECUADOR [J].
Almeida, R. ;
AlcivarAlcivar, I ;
Cabezas, M. ;
Fornasini, M. ;
Albert, A. .
VALUE IN HEALTH, 2016, 19 (03) :A233-A233
[7]  
Alvarez-Hernández E, 2012, REUMATOL CLIN, V8, P168, DOI [10.1016/j.reuma.2012.05.002, 10.1016/j.reumae.2012.06.018]
[8]   POTENTIAL COST-SAVINGS DUE TO THE APPLICATION OF A CENTER OF EXCELLENCE CARE MODEL IN RHEUMATOID ARTHRITIS IN COLOMBIA [J].
Alvis-Zakzuk, N. J. ;
Santos-Moreno, P. ;
Carrasquilla, M. ;
Alvis-Guzman, N. .
VALUE IN HEALTH, 2019, 22 :S241-S241
[9]   HOW EXPENSIVE IS TREATING PATIENTS IN A CENTER OF EXCELLENCE FOR RHEUMATOID ARTHRITIS IN COLOMBIA? [J].
Alvis-Zakzuk, N. J. ;
Santos-Moreno, P. ;
Villarreal Peralta, L. ;
Alvis-Guzman, N. ;
Carrasquilla, M. .
VALUE IN HEALTH, 2019, 22 :S242-S242
[10]   Rheumatoid arthritis and systemic lupus erythematosus: Pathophysiological mechanisms related to innate immune system [J].
Angelica Pabon-Porras, Maria ;
Molina-Rios, Sebastian ;
Bruce Florez-Suarez, Jorge ;
Ximena Coral-Alvarado, Paola ;
Mendez-Patarroyo, Paul ;
Quintana-Lopez, Gerardo .
SAGE OPEN MEDICINE, 2019, 7